

Director Dealing

Released : 01.08.2017

RNS Number : 6440M
Advanced Oncotherapy PLC
01 August 2017

ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")

Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company ("Ordinary Shares") at a price of 17.75 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the Company's issued share capital.

For further information, please contact:

Advanced Oncotherapy Plc

Dr. Michael Sinclair, Executive Chairman
Nicolas Serandour, CEO

www.avoplc.com

Tel: +44 20 3617 8728

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Paul McManus / Anna Dunphy

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS
The company news service from the London Stock Exchange

END

DSHBUGDRSSXBGRB